CELETTI, ANGELA
CELETTI, ANGELA
Istituto di Endocrinologia e Oncologia Sperimentale ''G. Salvatore'' - IEOS
Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents
2024 Caggiano, Rocco; Prokhorova, Evgeniia; Duma, Lena; Schützenhofer, Kira; Lauro, Raffaella; Catara, Giuliana; Melillo, Rosa Marina; Celetti, Angela; Smith, Rebecca; Weroha, S John; Kaufmann, Scott H; Ahel, Ivan; Palazzo, Luca
A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options
2022 Criscuolo, Daniela; Morra, Francesco; Celetti, Angela
The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma
2022 Morra, Francesco; Merolla, Francesco; Damia, Giovanna; Ricci, Francesca; Varricchio, Silvia; Ilardi, Gennaro; Arenare, Laura; Califano, Daniela; Napolitano, Virginia; Fruscio, Robert; Melillo, Rosa Marina; Palazzo, Luca; Celetti, Angela
Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer
2022 Miro, Caterina; Di Giovanni, Angelo; Murolo, Melania; Cicatiello, Annunziata Gaetana; Nappi, Annarita; Sagliocchi, Serena; Di Cicco, Emery; Morra, Francesco; Celetti, Angela; Pacifico, Francesco; Imbimbo, Ciro; Crocetto, Felice; Dentice, Monica
Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives
2021 Poltronieri, Palmiro; Celetti, Angela; Palazzo, Luca
The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis
2021 Morra, Francesco; Merolla, Francesco; Zito Marino, Federica; Catalano, Rosaria; Franco, Renato; Chieffi, Paolo; Celetti, Angela
Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma
2019 Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A
CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC
2019 Morra F.; Merolla F.; Picardi I.; Russo D.; Ilardi G.; Varricchio S.; Liotti F.; Pacelli R.; Palazzo L.; Mascolo M.; Celetti A.; Staibano S.
CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology
2019 Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A.
New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment
2019 Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A.
NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells.
2019 Cerrato A; Morra F; Di Domenico I; Celetti A.
Epigenetics of oral and oropharyngeal cancers (Review)
2018 Russo, D; Merolla, F; Varricchio, S; Salzano, G; Zarrilli, G; Mascolo, M; Strazzullo, V; Di Crescenzo, Rm; Celetti, A; Ilardi, G
The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer
2018 Cerrato, Aniello; Visconti, Roberta; Celetti, Angela
CCDC6: The identity of a protein known to be partner in fusion
2017 Cerrato A.; Merolla F.; Morra F.; Celetti A.
FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC?
2017 Daniela, R; Francesco, M; Mascolo, M; Ilardi, G; Romano, S; Varricchio, S; Napolitano, V; Celetti, A; Postiglione, L; Di Lorenzo, Pp; Califano, L; Dell'Aversana, Go; Astarita, F; Romano, Mf; Staibano, S
The between now and then of lung cancer chemotherapy and immunotherapy
2017 Visconti, R; Morra, F; Guggino, G; Celetti, A
The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.
2017 Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela
USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs
2017 Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A.
MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors
2016 Rossi, M; Colecchia, D; Ilardi, G; Acunzo, M; Nigita, G; Sasdelli, F; Celetti, A; Strambi, A; Staibano, S; Croce, Cm; Chiariello, M
Nucleotide Excision Repair and head and neck cancers.
2016 Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| Suppression of ADP-ribosylation reversal triggers cell vulnerability to alkylating agents | 1-gen-2024 | Caggiano, Rocco; Prokhorova, Evgeniia; Duma, Lena; Schützenhofer, Kira; Lauro, Raffaella; Catara, Giuliana; Melillo, Rosa Marina; Celetti, Angela; Smith, Rebecca; Weroha, S John; Kaufmann, Scott H; Ahel, Ivan; Palazzo, Luca | |
| A xCT role in tumour-associated ferroptosis shed light on novel therapeutic options | 1-gen-2022 | Criscuolo, Daniela; Morra, Francesco; Celetti, Angela | |
| The disruption of the CCDC6 - PP4 axis induces a BRCAness like phenotype and sensitivity to PARP inhibitors in high-grade serous ovarian carcinoma | 1-gen-2022 | Morra, Francesco; Merolla, Francesco; Damia, Giovanna; Ricci, Francesca; Varricchio, Silvia; Ilardi, Gennaro; Arenare, Laura; Califano, Daniela; Napolitano, Virginia; Fruscio, Robert; Melillo, Rosa Marina; Palazzo, Luca; Celetti, Angela | |
| Thyroid hormone and androgen signals mutually interplay and enhance inflammation and tumorigenic activation of tumor microenvironment in prostate cancer | 1-gen-2022 | Miro, Caterina; Di Giovanni, Angelo; Murolo, Melania; Cicatiello, Annunziata Gaetana; Nappi, Annarita; Sagliocchi, Serena; Di Cicco, Emery; Morra, Francesco; Celetti, Angela; Pacifico, Francesco; Imbimbo, Ciro; Crocetto, Felice; Dentice, Monica | |
| Mono(ADP-ribosyl)ation Enzymes and NAD+ Metabolism: A Focus on Diseases and Therapeutic Perspectives | 1-gen-2021 | Poltronieri, Palmiro; Celetti, Angela; Palazzo, Luca | |
| The tumour suppressor CCDC6 is involved in ROS tolerance and neoplastic transformation by evading ferroptosis | 1-gen-2021 | Morra, Francesco; Merolla, Francesco; Zito Marino, Federica; Catalano, Rosaria; Franco, Renato; Chieffi, Paolo; Celetti, Angela | |
| Analysis of CCDC6 as a novel biomarker for the clinical use of PARP1 inhibitors in malignant pleural mesothelioma | 1-gen-2019 | Morra, F; Merolla, F; D'Abbiero, D; Ilardi, G; Campione, S; Monaco, R; Guggino, G; Ambrosio, F; Staibano, S; Cerrato, A; Visconti, R; Celetti, A | |
| CAF-1 subunits levels suggest combined treatments with PARP-inhibitors and ionizing radiation in advanced HNSCC | 1-gen-2019 | Morra F.; Merolla F.; Picardi I.; Russo D.; Ilardi G.; Varricchio S.; Liotti F.; Pacelli R.; Palazzo L.; Mascolo M.; Celetti A.; Staibano S. | |
| CCDC6 and USP7 expression levels suggest novel treatment options in high-grade urothelial bladder cancer 11 Medical and Health Sciences 1112 Oncology and Carcinogenesis 06 Biological Sciences 0601 Biochemistry and Cell Biology | 1-gen-2019 | Morra F.; Merolla F.; Criscuolo D.; Insabato L.; Giannella R.; Ilardi G.; Cerrato A.; Visconti R.; Staibano S.; Celetti A. | |
| New combinatorial strategies to improve the PARP inhibitors efficacy in the urothelial bladder Cancer treatment | 1-gen-2019 | Criscuolo D.; Morra F.; Giannella R.; Visconti R.; Cerrato A.; Celetti A. | |
| NSCLC Mutated Isoforms of CCDC6 Affect the Intracellular Distribution of the Wild Type Protein Promoting Cisplatinum Resistance and PARP Inhibitors Sensitivity in Lung Cancer Cells. | 1-gen-2019 | Cerrato A; Morra F; Di Domenico I; Celetti A. | |
| Epigenetics of oral and oropharyngeal cancers (Review) | 1-gen-2018 | Russo, D; Merolla, F; Varricchio, S; Salzano, G; Zarrilli, G; Mascolo, M; Strazzullo, V; Di Crescenzo, Rm; Celetti, A; Ilardi, G | |
| The rationale for druggability of CCDC6-tyrosine kinase fusions in lung cancer | 1-gen-2018 | Cerrato, Aniello; Visconti, Roberta; Celetti, Angela | |
| CCDC6: The identity of a protein known to be partner in fusion | 1-gen-2017 | Cerrato A.; Merolla F.; Morra F.; Celetti A. | |
| FKBP51 immunohistochemical expression: A new prognostic biomarker for OSCC? | 1-gen-2017 | Daniela, R; Francesco, M; Mascolo, M; Ilardi, G; Romano, S; Varricchio, S; Napolitano, V; Celetti, A; Postiglione, L; Di Lorenzo, Pp; Califano, L; Dell'Aversana, Go; Astarita, F; Romano, Mf; Staibano, S | |
| The between now and then of lung cancer chemotherapy and immunotherapy | 1-gen-2017 | Visconti, R; Morra, F; Guggino, G; Celetti, A | |
| The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells. | 1-gen-2017 | Morra, Francesco; Merolla, Francesco; Napolitano, Virginia; Ilardi, Gennaro; Miro, Caterina; Paladino, Simona; Staibano, Stefania; Cerrato, Aniello; Celetti, Angela | |
| USP7 inhibitors, downregulating CCDC6, sensitize lung neuroendocrine cancer cells to PARP-inhibitor drugs | 1-gen-2017 | Malapelle U.; Morra F.; Ilardi G.; Visconti R.; Merolla F.; Cerrato A.; Napolitano V.; Monaco R.; Guggino G.; Monaco G.; Staibano S.; Troncone G.; Celetti A. | |
| MAPK15 upregulation promotes cell proliferation and prevents DNA damage in male germ cell tumors | 1-gen-2016 | Rossi, M; Colecchia, D; Ilardi, G; Acunzo, M; Nigita, G; Sasdelli, F; Celetti, A; Strambi, A; Staibano, S; Croce, Cm; Chiariello, M | |
| Nucleotide Excision Repair and head and neck cancers. | 1-gen-2016 | Merolla, Francesco; Mascolo, Massimo; Ilardi, Gennaro; Siano, Maria; Russo, Daniela; Graziano, Vincenzo; Celetti, Angela; Staibano, Stefania |